10/19/2026
Big news for our whole Porphamily, and especially our EPP and XLP community! This morning Disc Medicine announced positive Phase 3 results for bitopertin, an investigational treatment for erythropoietic protoporphyria.
To every patient and family who joined the Phase 2 and Phase 3 trials, and to every Phase 3 participant who completed the study and entered their data for one another: thank you. Research cannot happen without you, and it is because of you that bitopertin is headed back to the FDA for review.
This community cannot afford more delay. We urge the FDA to recognize the undeniable need in EPP and follow the data. Our community's voice echoes it: this treatment has changed lives and brought freedom. Together with our expert physicians, Disc, and regulators, let's get it to everyone who needs it.
Join us Wednesday at 6:00 PM ET for a community call with UPA and Disc leadership.
Register for link: https://www.porphyria.org/events/bitopertincall-phase3
Press release: https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-success-all-primary-and-secondary